Header Logo

Connection

Yehuda Handelsman to Risk Factors

Back to Details
This is a "connection" page, showing publications Yehuda Handelsman has written about Risk Factors.
Yehuda Handelsman
Connection Strength
1.524
Risk Factors
  1. Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2023 02; 37(2):108389.
    View in: PubMed
    Score: 0.172
  2. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. Endocr Pract. 2020 Oct; 26(10):1196-1224.
    View in: PubMed
    Score: 0.147
  3. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes. Adv Ther. 2019 10; 36(10):2567-2586.
    View in: PubMed
    Score: 0.136
  4. Gerald Reaven: A man for our times. Diab Vasc Dis Res. 2019 03; 16(2):113-115.
    View in: PubMed
    Score: 0.132
  5. Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population. Clin Cardiol. 2019 Mar; 42(3):391-399.
    View in: PubMed
    Score: 0.132
  6. PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review. J Am Heart Assoc. 2018 06 22; 7(13).
    View in: PubMed
    Score: 0.126
  7. Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II. Diabetes Obes Metab. 2017 07; 19(7):989-996.
    View in: PubMed
    Score: 0.116
  8. Diabetes treatment over age 65: Is worse control really better? J Diabetes. 2017 May; 9(5):428-430.
    View in: PubMed
    Score: 0.115
  9. Overcoming obstacles in risk factor management in type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2011 Aug; 13(8):613-20.
    View in: PubMed
    Score: 0.078
  10. Metabolic syndrome pathophysiology and clinical presentation. Toxicol Pathol. 2009 Jan; 37(1):18-20.
    View in: PubMed
    Score: 0.065
  11. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. Expert Rev Cardiovasc Ther. 2022 Aug; 20(8):609-625.
    View in: PubMed
    Score: 0.042
  12. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects. Vasc Health Risk Manag. 2020; 16:403-418.
    View in: PubMed
    Score: 0.037
  13. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017 12; 5(12):941-950.
    View in: PubMed
    Score: 0.030
  14. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA. 2017 Jul 04; 318(1):45-56.
    View in: PubMed
    Score: 0.029
  15. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes. 2017 02; 66(2):241-255.
    View in: PubMed
    Score: 0.028
  16. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013 Mar-Apr; 19(2):327-36.
    View in: PubMed
    Score: 0.022
  17. The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations. Endocr Pract. 2013 Jan-Feb; 19(1):100-6.
    View in: PubMed
    Score: 0.022
  18. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: executive summary. Endocr Pract. 2012 Mar-Apr; 18(2):269-93.
    View in: PubMed
    Score: 0.020
  19. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2012 Mar-Apr; 18 Suppl 1:1-78.
    View in: PubMed
    Score: 0.020
  20. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008 Oct; 14(7):933-46.
    View in: PubMed
    Score: 0.016
  21. Hypoglycemia in the intensive care unit. Curr Opin Clin Nutr Metab Care. 2007 Mar; 10(2):193-6.
    View in: PubMed
    Score: 0.014
  22. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract. 2006 Jan-Feb; 12 Suppl 1:6-12.
    View in: PubMed
    Score: 0.013
  23. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003 May-Jun; 9(3):237-52.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.